OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Automated inline dilution system can reduce downstream processing delays.
Adoption of single-use technologies prompts need for PAT-friendly sensors.
Defining a holistic approach to validation and quality assurance for finished drug products.
Creativity and collaboration are required to overcome complex method development challenges.
January 27, 2021
Sanofi will offer access to its infrastructure and expertise to help BioNTech produce over 125 million doses of its COVID-19 vaccine in Europe.
January 26, 2021
Connected, integrated bioprocessing enterprises with greater data analytics capabilities are coming.
Clinical material for a Theratechnologies product in development will be produced at PPS’ manufacturing facility in Lexington, KY.
A complicated vaccination rollout and mixed messages may derail the pandemic endgame
Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.
January 18, 2021
The 40,000-ft.2 facility will feature eight cleanrooms with configurations for the production of cell and viral vector products.
Henogen will be integrated into Thermo Fisher’s Pharma Services business within its Laboratory Products and Services segment.
January 15, 2021
The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.
January 14, 2021
The 17,000 m2 facility will serve as a process development and manufacturing site for Chinese companies developing medicines as well as multinationals with manufacturing requirements in China.
January 13, 2021
Acorda’s Chelsea, MA facility will serve as a global center of excellence in the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging.
January 11, 2021
Baxter will provide commercial-scale manufacturing services at its Halle/Westfalen, Germany facility to prepare Novavax’s COVID-19 vaccine candidate for distribution in the United Kingdom and European markets.
The company plans to expand its global production capacity across six existing manufacturing facilities in Europe and the United States, as well as a new manufacturing facility in the US.
January 07, 2021
The new facility, which will be operated by Fujifilm Diosynth Biotechnologies, will provide large-scale cell-culture manufacturing of bulk drug substance with 8 x 20,000-L bioreactors.
Intravacc and Cristal Therapeutics have entered into a strategic collaboration for the development of novel vaccine programs against human diseases.
January 06, 2021
Demand for specific advanced laboratory skills creates a positive employment market.
January 04, 2021
Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.
BioPharm International interviewed Cloudleaf about trends in tracking vaccines through the supply chain.
January 02, 2021
After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.
Essential bio/pharma employees show hard work and dedication can pay off, for patients.
Advances in development, data management, and automation, and closer collaboration with contract development and manufacturing partners, are pushing more therapies closer to commercialization.